It’s a busy time at Avidity Biosciences. The La Jolla, California company, which went public during Covid last year, is gearing up to begin a Phase 1/2 clinical trial by the end of 2021 to test its novel antibody oligonucleotide conjugate that can treat myotonic dystrophy, a rare muscle genetic disorder. Myotonic dystrophy currently has no treatment.
For Sarah Boyce, the company’s CEO, seeing a successful commercial path for its therapeutic candidate, is perhaps equally as important as the culture of diversity and inclusion that she is committed to building at the company. Avidity’s board has an equal number of men and women. In this episode of MedCity’s Pivot podcast, Boyce stressed how having been in situations where men mistook her for being the responsible for taking meeting minutes, or telling her what to wear, she now is committed to building a workplace where women can feel empowered and thrive. A moment of epiphany came at an annual J.P. Morgan Healthcare Conference.
